<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1692-7273</journal-id>
<journal-title><![CDATA[Revista Ciencias de la Salud]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Cienc. Salud]]></abbrev-journal-title>
<issn>1692-7273</issn>
<publisher>
<publisher-name><![CDATA[Editorial Universidad del Rosario]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1692-72732017000300387</article-id>
<article-id pub-id-type="doi">10.12804/revistas.urosario.edu.co/revsalud/a.6122</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Utilización de medicamentos antidepresivos en población adolescente de Colombia: un estudio tipo prescripción-indicación]]></article-title>
<article-title xml:lang="en"><![CDATA[Use of Antidepressant Drugs by Colombian Adolescents: A Study of Prescription Indication]]></article-title>
<article-title xml:lang="pt"><![CDATA[Utilização de Medicamentos Antidepressivos em População Adolescente da Colômbia: um Estudo Tipo Prescrição-Indicação]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Machado-Duque]]></surname>
<given-names><![CDATA[Manuel Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Echeverri-Chabur]]></surname>
<given-names><![CDATA[Jorge Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Machado-Alba]]></surname>
<given-names><![CDATA[Jorge Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Tecnológica de Pereira Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia ]]></institution>
<addr-line><![CDATA[Pereira ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Tecnológica de Pereira Departamento de Psiquiatría ]]></institution>
<addr-line><![CDATA[Pereira ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<volume>15</volume>
<numero>3</numero>
<fpage>387</fpage>
<lpage>396</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S1692-72732017000300387&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S1692-72732017000300387&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S1692-72732017000300387&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo:  Determinar las indicaciones de uso de antidepresivos en adolescentes (14-19 años) de Colombia.  Materiales y métodos : Estudio de corte transversal donde se incluyeron datos de pacientes adolescentes, de cualquier sexo, que estuvieran recibiendo algún antidepresivo entre enero de 2015 y junio de 2016. Se revisaron las historias clínicas en las que se evaluaron variables sociodemográficas, farmacológicas, clínicas, incluidos el diagnóstico, la indicación aprobada o no y las comedicaciones. Se realizaron análisis multivariados.  Resultados:  Se evaluaron 350 adolescentes tratados con antidepresivos, con edad media de 16,3 ± 1,4 años, ligero predominio femenino, con 209 pacientes (59,7%). La mayoría de prescripciones fueron realizadas por médico general (n=258; 73,7%). Los antidepresivos más utilizados fueron fluoxetina (n=130; 37,1 %), sertralina (n=56; 16,0%) y trazodona (n=47; 13,4%). Las principales indicaciones de uso fueron depresión (n=92; 26,3%), ansiedad (n=53; 15,1%), migraña (n=48; 13,7 %), control de abuso de consumo de sustancias psicoactivas (n=34; 9,7 %) e insomnio (n=20; 5,7 %). Solamente 150 (42,9%) prescripciones se realizaron según aprobación por parte de agencias reguladoras. El análisis multivariado de la prescripción en indicaciones no aprobadas mostró que tener depresión (OR: 0,004; 1095%: 0,001-0,018), ansiedad (OR: 0,028; 1095%: 0,010-0,076) o trastorno afectivo bipolar (OR: 0,071; IC95%:0,011-0,461) estaban asociadas a una menor probabilidad de uso por fuera del aprobado.  Discusión:  La prescripción de los fármacos antidepresivos en pacientes adolescentes colombianos se está haciendo en especial con fluoxetina, sertralina y trazodona, principalmente para indicaciones no aprobadas. No hay una guía de práctica clínica en el país para el uso de estos medicamentos en la población adolescente.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective:  To determine the indications for the use of antidepressants by adolescents (14- 19 years old) in Colombia.  Materials and methods:  A cross-sectional study using data on adolescent patients of both sexes who were receiving antidepressants in January 2015-June 2016. Medical records were reviewed to assess sociodemographic, pharmacological, and clinical variables including diagnosis, indication (approved or not) and co-medications. Multivariate analyses were performed.  Results:  A total of 350 adolescents treated with antidepressants were evaluated, with a mean age of 16.3±1.4 years and a slight predominance of females (59.7%). Most antidepressants were prescribed by general practitioners (n=258; 73.7%). The most commonly used antidepressants were fluoxetine (n=130; 37.1%), sertraline (n=56; 16.0%), and trazodone (n=47; 13.4%). The main indications for use were depression (n = 92; 26.3%), anxiety (n=53; 15.1%), migraine (n=48; 13.7%), abuse of psychoactive substances (n=34; 9.7%), and insomnia (n=20; 5.7%). Only 150 (42.9%) prescriptions were in conformity with approval by regulatory agencies. Multivariate analysis of unapproved prescription indications showed that suffering from depression (OR: 0.004; 95% ci: 0.001-0.018), anxiety (OR: 0.028; 95% CI: 0.010-0.076), or bipolar affective disorder (OR: 0.071; IC95 %: 0.011-0.461) was associated with a lower likelihood that drug use was unapproved.  Discussion:  The prescribing of antidepressant drugs to adolescent Colombian patients is being practiced most frequently with fluoxetine, sertraline, and trazodone, mainly for unapproved indications. There are no guidelines in Colombia for clinical practice, including the use of these drugs by the adolescent population.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Introdução:  Determinar as indicações de uso de antidepressivos em adolescentes (14-19 anos) da Colômbia.  Materiais e métodos:  Estudo de corte transversal onde incluíram-se dados de pacientes adolescentes, de qualquer sexo, que estivessem recebendo algum antidepressivo entre janeiro de 2015 e junho de 2016. Se revisaram as histórias clínicas avaliando variáveis sociodemográficas, farmacológicas, clínicas, incluindo o diagnóstico, indicação aprovada ou não e co-medicações. Se realizaram análises multivariadas.  Resultados:  Avaliaram-se 350 adolscentes tratados com anti-depressivos, com idade média de 16,3 ± 1,4 anos, ligeiro predomínio feminino com 209 pacientes (59,7%). A maioria de prescrições foram realizadas por médico geral (n=258; 73,7%). Os antidepressivos mais utilizados foram fluoxetina (n=130; 37,1%), sertralina (n=56; 16,0%) e trazodona (n=47; 13,4 %). As principais indicações de uso foram depressão (n=92; 26,3%), ansiedade (n=53; 15,1%), enxaqueca (n=48; 13,7%), controle de abuso de consumo de sustâncias psicoativas (n=34; 9,7%), e insónia (n=20; 5,7%). Só 150 (42,9%) prescrições se realizaram segundo aprovação por parte de agências reguladoras. A análise multivariada da prescrição em indicações não aprovadas mostrou que ter depressão (OR: 0,004; IC95%:0,001-0,018), ansiedade (OR: 0,028; IC95%:0,010-0,076) ou transtorno afetivo bipolar (OR: 0,071; IC95%:0,011-0,461) se associaram com menor probabilidade de que o seu uso estivesse por fora do aprovado.  Discussão:  A prescrição de fármacos antidepressivos em pacientes adolescentes colombianos está-se fazendo especialmente com fluoxetina, sertralina e trazodona, principalmente para indicações não aprovadas. Não há uma guia de prática clínica no país para o uso destes medicamentos na população adolescente.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Antidepresivos]]></kwd>
<kwd lng="es"><![CDATA[depresión]]></kwd>
<kwd lng="es"><![CDATA[adolescente]]></kwd>
<kwd lng="es"><![CDATA[prescripciones de medicamentos]]></kwd>
<kwd lng="es"><![CDATA[farmacoepidemiología]]></kwd>
<kwd lng="en"><![CDATA[Antidepressive agents]]></kwd>
<kwd lng="en"><![CDATA[depression]]></kwd>
<kwd lng="en"><![CDATA[adolescent]]></kwd>
<kwd lng="en"><![CDATA[drug prescriptions]]></kwd>
<kwd lng="en"><![CDATA[pharmacoepidemiology]]></kwd>
<kwd lng="pt"><![CDATA[Antidepressivos]]></kwd>
<kwd lng="pt"><![CDATA[Depressão]]></kwd>
<kwd lng="pt"><![CDATA[Adolescente]]></kwd>
<kwd lng="pt"><![CDATA[Prescrições de Medicamentos]]></kwd>
<kwd lng="pt"><![CDATA[Farmacoepidemiologia]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Le Noury]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Nardo]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Healy]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Jureidini]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Raven]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tufanaru]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Restoring Study 329: Efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2015</year>
<numero>351</numero>
<issue>351</issue>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keller]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Ryan]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
<name>
<surname><![CDATA[Strober]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Klein]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Kutcher]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Birmaher]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[a]]></surname>
<given-names><![CDATA[et]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[. Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial]]></article-title>
<source><![CDATA[J Am Acad Child Adolesc Psychiatry]]></source>
<year>2001</year>
<volume>40</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>762-72</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Julious]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and suicidal risk for antidepressants in paediatric and adolescent patients.]]></article-title>
<source><![CDATA[Stat Methods Med Res]]></source>
<year>2013</year>
<volume>22</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>190-218</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Birkenhager]]></surname>
<given-names><![CDATA[TK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Both paroxetine and imipramine appear to be ineffective in adolescents with major depression, furthermore doubts have risen about their safety]]></article-title>
<source><![CDATA[Evid Based Med]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Isacsson]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ahlner]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antidepressants and the risk of suicide in young persons-Prescription trends and toxicological analyses]]></article-title>
<source><![CDATA[Acta Psychiatr Scand]]></source>
<year>2014</year>
<volume>129</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>296-302</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morrison]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adolescent angst OR true intent? Suicidal behavior, risk, and neurobiological mechanisms in depressed children and teenagers taking antidepressants]]></article-title>
<source><![CDATA[Int J Emerg Ment Health]]></source>
<year>2014</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>247-50</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arango-Dávila]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Rojas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Análisis de los aspectos asociados a la enfermedad mental en Colombia y la formación en psiquiatría]]></article-title>
<source><![CDATA[Rev Col Psiquiatr]]></source>
<year>2008</year>
<numero>4</numero>
<issue>4</issue>
<page-range>538-63</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wohlfarth]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kalverdijk]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rademaker]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Schothorst]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Minderaa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gispen-de Wied]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Psychopharmacology for children: From off label use to registration]]></article-title>
<source><![CDATA[Eur Neuropsychopharmacol]]></source>
<year>2009</year>
<volume>19</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>603-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Egberts]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Mehler-Wex]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gerlach]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutic drug monitoring in child and adolescent psychiatry]]></article-title>
<source><![CDATA[Pharmacopsychiatry]]></source>
<year>2011</year>
<volume>44</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>249-53</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eapen]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Crncec]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Strategies and challenges in the management of adolescent depression]]></article-title>
<source><![CDATA[Curr Opin Psychiatry]]></source>
<year>2012</year>
<volume>25</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>7-13</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perspectives on the efficacy of antidepressants for child and adolescent depression]]></article-title>
<source><![CDATA[PLoS Med]]></source>
<year>2006</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meredith]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Stein]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
<name>
<surname><![CDATA[Paddock]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Jaycox]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Quinn]]></surname>
<given-names><![CDATA[VP]]></given-names>
</name>
<name>
<surname><![CDATA[Chandra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perceived barriers to treatment for adolescent depression]]></article-title>
<source><![CDATA[Med Care]]></source>
<year>2009</year>
<volume>47</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>677-85</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cleare]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pariante]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Christmas]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Cowen]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines]]></article-title>
<source><![CDATA[J Psychopharmacol]]></source>
<year>2015</year>
<volume>29</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>459-525</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gordon]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Melvin]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Do antidepressants make children and adolescents suicidal?]]></article-title>
<source><![CDATA[J Paediatr Child Health]]></source>
<year>2014</year>
<volume>50</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>847-54</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
